Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial

Figures & data

Figure 1.  Model structure overview.

Figure 2.  Model cohort simulation.

Table 1.  Direct medical cost estimates for cardiovascular events.

CVD event direct costs (2008 $US)	Event year	Subsequent years	Source
Non-fatal MI costs	13,255	5139	Pignone23
			Schleinitz27
			Beinart28
			Chan29
			Kauf30
PTCA costs	14,712	0	Schleinitz27
			Beinart28
			Chan29
			Kauf30
CABG costs	39,409	0	Schleinitz27
			Beinart28
			Chan29
			Kauf30
			Puskas31
Unstable angina costs	5827	2878	Pignone23
			Beinart28
Non-fatal stroke costs	19,096	11,084	Pignone23
			Schleinitz27
			Chan29
			O’Brien32
			Lee33
MI death	16,951	0	Pignone23
			Schleinitz27
			Sullivan15
Stroke death	19,652	0	Pignone23
			Schleinitz27
			Sullivan15
Other CVD death	2500	0	Assumption
Non-CVD death costs	5000	0	Assumption
Average CVD/CHD death costs (Secondary CVD Prevention)	7625	0	Weighted average

Table 2.  Disutilities for CVD events.

CVD event disutilities	Event year	Subsequent years
Non-fatal MI disutility	0.24	0.24
PTCA disutility	0.0175	0
CABG disutility	0.037	0
Unstable angina disutility	0.23	0
Non-fatal stroke disutility	0.37	0.37
CVD death disutility	0.5	1.0
Non-CVD death disutility	0.5	1.0

Source: Table 61, Statins for the prevention of coronary events, HTA report: Ward S, Lloyd Jones M, Pandor A7. PTCA/CABG values per Scuffham PA and Kosa J34.

Table 3.  Base case (intermediate and high risk patients) for predicted life-years gained, therapy cost, impact on major cardiovascular events and cost effectiveness in the total sample per 1,000 patients.

Total sample	Time horizon post-therapy initiation
	10-year			20-year			Lifetime
	Placebo	RSV	Difference	Placebo	RSV	Difference	Placebo	RSV	Difference
Total life-years	7918	7979	61	11,820	12,024	204	13,117	13,415	298
Total quality-adjusted life-years	6252	6352	99	9066	9320	254	9937	10,271	335
Total direct costs ($1000s)	$6563	$10,973	$4409	$14,692	$17,419	$2726	$19,804	$22,169	$2364
Cost per life-year gained ICER			$72,657			$13,340			$7929
Cost per quality-adjusted life-years gained ICER			$44,466			$10,743			$7062

RSV, rosuvastatin; ICER, incremental cost-effectiveness ratio.

Figure 3.  One-way sensitivity analyses, lifetime horizon for at-risk population.

Figure 4.  Probabilistic sensitivity analysis (willingness-to-pay) for cost per quality-adjusted life-years gained over the lifetime.

Pignone M, Earnshaw S, Tice J, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336

 PubMed Web of Science ®Google Scholar

Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-259

 PubMed Web of Science ®Google Scholar

Beinart SC, Kolm P, Veledar E, et al. Long-term cost-effectiveness analysis of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention. J Am Coll Cardiol 2005;46:761-769

 PubMed Web of Science ®Google Scholar

Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high dose statin therapy in high risk patients with coronary heart disease. Circulation 2007;115:2398-2409

 PubMed Web of Science ®Google Scholar

Kauf TL, Velazquez EJ, Crosslin DR, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J 2006;151:206-212

 PubMed Web of Science ®Google Scholar

Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs. conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes. JAMA 2004;291:1841-1849

 PubMed Web of Science ®Google Scholar

O'Brien C, Gage B. Cost and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706

 PubMed Web of Science ®Google Scholar

Lee WC, Christensen MC, Josh, AV, et al. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis 2007;23:57-65

 PubMed Web of Science ®Google Scholar

Sullivan P, Arant T, Ellis S, et al. The cost-effectiveness analysis of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;10:1021-1033

 Web of Science ®Google Scholar

Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160, iii-iv

 Web of Science ®Google Scholar

Scuffham PA, Kosa J. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Cardiovasc Drugs Ther 2006;20:309-317

 PubMed Web of Science ®Google Scholar